tiprankstipranks
Advertisement
Advertisement

RNTX Stock Latest News

Rein Therapeutics Prices $50 Million Public Equity Offering
Company AnnouncementsRein Therapeutics Prices $50 Million Public Equity Offering
18d ago
8K
RNTX
Rein Therapeutics provides update on RENEW clinical trial
PremiumThe Fly
Rein Therapeutics provides update on RENEW clinical trial
23d ago
RNTX
Rein Therapeutics files to sell 30M shares of common stock
PremiumThe Fly
Rein Therapeutics files to sell 30M shares of common stock
24d ago
RNTX
RNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
RNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
RNTX
Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright
PremiumThe Fly
Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright
2M ago
RNTX
Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside
PremiumRatingsRein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside
2M ago
RNTX
Rein Therapeutics doses first patient in Phase 2 trial of LTI-03
Premium
The Fly
Rein Therapeutics doses first patient in Phase 2 trial of LTI-03
3M ago
RNTX
Rein Therapeutics Completes Private Placement of Notes
Premium
Company Announcements
Rein Therapeutics Completes Private Placement of Notes
3M ago
8K
RNTX
Rein Therapeutics Announces Immediate Board Director Resignation
PremiumCompany Announcements
Rein Therapeutics Announces Immediate Board Director Resignation
3M ago
8K
RNTX
Rein Therapeutics downgraded to Hold from Buy at Brookline
PremiumThe Fly
Rein Therapeutics downgraded to Hold from Buy at Brookline
4M ago
RNTX
Rein Therapeutics receives orphan drug designation from EMA for LTI-03
PremiumThe Fly
Rein Therapeutics receives orphan drug designation from EMA for LTI-03
4M ago
RNTX
Rein Therapeutics Raises Capital via Private Note Offering
PremiumCompany Announcements
Rein Therapeutics Raises Capital via Private Note Offering
4M ago
8K
RNTX
Rein Therapeutics Ends Key Financial Agreements
PremiumCompany AnnouncementsRein Therapeutics Ends Key Financial Agreements
5M ago
8K
RNTX
Rein Therapeutics: Buy Rating Driven by Innovative IPF Treatment and Strong Growth Potential
Premium
Ratings
Rein Therapeutics: Buy Rating Driven by Innovative IPF Treatment and Strong Growth Potential
6M ago
RNTX
Rein Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Rein Therapeutics Reports Q3 2025 Financial Results
6M ago
RNTX
Rein Therapeutics’s LTI-03 Gains Momentum with FDA Clearance and Promising Trial Developments
PremiumRatings
Rein Therapeutics’s LTI-03 Gains Momentum with FDA Clearance and Promising Trial Developments
7M ago
RNTX
Rein Therapeutics announces publication on LTI-03
PremiumThe Fly
Rein Therapeutics announces publication on LTI-03
7M ago
RNTX
Rein Therapeutics upgraded to Buy from Hold at Brookline
PremiumThe Fly
Rein Therapeutics upgraded to Buy from Hold at Brookline
7M ago
RNTX
Rein Therapeutics Resumes Phase 2 Trial for LTI-03
PremiumCompany Announcements
Rein Therapeutics Resumes Phase 2 Trial for LTI-03
7M ago
8K
RNTX
Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03
PremiumThe FlyRein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03
7M ago
RNTX
Rein Therapeutics Secures Third Pre-Paid Advance
Premium
Company Announcements
Rein Therapeutics Secures Third Pre-Paid Advance
7M ago
8K
RNTX
Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03
Premium
The Fly
Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03
8M ago
RNTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >